Open, randomized, multi-center phase II study comparing efficacy and tolerability of Erlotinib vs. Carboplatin/Vinorelbin in elderly patients (>70 years of age) with untreated non-small cell lung cancer
David Felix Heigener, K.-M. Deppermann, Joachim von Pawel et al. · Lung Cancer · 2014
Cited by 25 works. doi:10.1016/j.lungcan.2014.01.024
Authors
- David Felix Heigener
- K.-M. Deppermann
- Joachim von Pawel
- Jürgen R. Fischer
- C. Kortsik
- Sabine Bohnet
- M. von Eiff
- W. Koester
- Michael Thomas
- Ph. A. Schnabel
- Martin Reck
References
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
- Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
- Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study
- Gesundheitsberichterstattung des Bundes
- Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial
- Erlotinib for Frontline Treatment of Advanced Non–Small Cell Lung Cancer: a Phase II Study
- Chemotherapy and Survival Benefit in Elderly Patients With Advanced Non–Small-Cell Lung Cancer
- The ELVIS Trial: A Phase III Study of Single-Agent Vinorelbine as First-Line Treatment in Elderly Patients with Advanced Non-Small Cell Lung Cancer
- First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial